Parvis S.
- Country
- Germany
- Department
- Klinik für Hämatologie, Onkologie und Palliativmedizin
Research Overview
- Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Patients With Previously Treated TROP2-Positive Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase 3 Randomized Open‑Label Trial of ABBV‑706 versus Standard of Care in Relapsed/Refractory Small Cell Lung Cancer
- Phase 3 Evaluation of Pembrolizumab and Olaparib with Chemoradiation in Unresectable Stage III Non-Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 156 of 353 partner sites.
Specializations
Lung Cancer Therapeutics
The investigator specializes in treating various forms of lung cancer, with particular emphasis on non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Their research encompasses both metastatic and locally advanced disease states.
- Squamous and Non-squamous NSCLC
- Limited Disease SCLC
- PD-L1 Expressing Tumors
Their work includes evaluation of novel therapeutic combinations for treating advanced stages of lung cancer.
Immunotherapy Applications
The investigator focuses on advancing immunotherapy treatments through combination approaches. Their expertise includes studies with various immunotherapeutic agents including pembrolizumab, durvalumab, and novel compounds.
- Combination Immunotherapy
- Chemoimmunotherapy
- Novel Immunotherapy Agents
Research includes evaluation of concurrent treatment strategies with chemotherapy and radiation therapy.
Supportive Care
The investigator addresses treatment-related complications, particularly focusing on chemotherapy-induced polyneuropathy (CIPN). Their research includes investigation of preventive approaches and symptom management.
- Neuropathy Prevention
- Quality of Life Studies
- Supportive Treatment Approaches
Their work aims to improve patient outcomes through better management of treatment side effects.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.